- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- Fact Check
- Bone Health Fact Check
- Brain Health Fact Check
- Cancer Related Fact Check
- Child Care Fact Check
- Dental and oral health fact check
- Diabetes and metabolic health fact check
- Diet and Nutrition Fact Check
- Eye and ENT Care Fact Check
- Fitness fact check
- Gut health fact check
- Heart health fact check
- Kidney health fact check
- Medical education fact check
- Men's health fact check
- Respiratory fact check
- Skin and hair care fact check
- Vaccine and Immunization fact check
- Women's health fact check
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
Gefapixant Effective treatment option for Chronic Cough
Chronic cough can be a challenging condition to manage, especially when it doesn't respond to conventional treatments. In the search for new therapies, gefapixant has emerged as a potential option for patients with refractory or unexplained chronic cough. A recent systematic review and meta-analysis published in JAMA Network by Elena Kum and colleagues aimed to evaluate the efficacy and tolerability of gefapixant in this patient population.
● Study Selection: The researchers analysed data from nine randomised clinical trials involving 2,980 patients with refractory or unexplained chronic cough.
● Gefapixant at a dose of 45 mg orally twice daily led to a 17.6% reduction in awake cough frequency compared to a placebo (moderate certainty).
● Cough severity, measured using a 100-mm visual analog scale, showed a significant improvement with gefapixant, with a mean difference of -6.2 mm (high certainty).
● Cough-specific quality of life, assessed with the Leicester Cough Questionnaire, improved by 1.0 point (moderate certainty).
Tolerability:
● Gefapixant, at a dose of 45 mg twice daily, was associated with an increase in treatment-related adverse events (moderate certainty).
● Taste-related adverse events were also more common with gefapixant at this dose (high certainty).
● Overall, gefapixant demonstrated modest improvements in cough frequency, cough severity, and cough-specific quality of life in patients with refractory or unexplained chronic cough. However, it was associated with an increase in taste-related adverse events.
These findings suggest that gefapixant may offer a potential therapeutic option for individuals with chronic cough who have not responded to other treatments. Clinicians should weigh the benefits and risks of this medication when considering it for their patients.
Reference:
Kum, E., Patel, M., Diab, N., Wahab, M., Zeraatkar, D., Chu, D. K., O’Byrne, P. M., Guyatt, G. H., & Satia, I. (2023). Efficacy and tolerability of gefapixant for treatment of refractory or unexplained chronic cough: A systematic review and dose-response meta-analysis. JAMA: The Journal of the American Medical Association. https://doi.org/10.1001/jama.2023.18035
Dr Kamal Kant Kohli-MBBS, DTCD- a chest specialist with more than 30 years of practice and a flair for writing clinical articles, Dr Kamal Kant Kohli joined Medical Dialogues as a Chief Editor of Medical News. Besides writing articles, as an editor, he proofreads and verifies all the medical content published on Medical Dialogues including those coming from journals, studies,medical conferences,guidelines etc. Email: drkohli@medicaldialogues.in. Contact no. 011-43720751